Terbutaline

Pregnancy & gynaecology-specific. Every dose row is source-referenced; verify against institutional protocols.

TerbutalineBeta-2 agonist

Regimens checked: 2026-10-17. Each indication has its own preparation, limits and safety checks.

Terbutaline: indication-specific regimens
Indication	Dose	Route	Frequency	Duration / preparation	Maximum	Monitoring / cautions
Hospital external cephalic version after eligibility assessment, consent and baseline CTG NHS Greater Glasgow and Clydechecked	250 micrograms, 10 minutes before ECV	Subcutaneous	One pre-procedure dose	One ECV attempt episode; not a maintenance preterm-labour regimen · 0.5 mg/mL ampoule: withdraw 0.5 mL =250 micrograms. This row is SC, not an interchangeable IV bolus Assess RhD status and provide indicated anti-D after ECV.	250 micrograms for the cited ECV regimen; no automatic repeat	Monitor Maternal pulse/BP before treatment and pulse 5 minutes after; fetal assessment/CTG and immediate caesarean capability Contraindications / cautions Cardiac disease; caution in diabetes and pre-eclampsia; ECV contraindications must be excluded

Pregnancy safety

Short procedural ECV use after obstetric assessment

Lactation

Single procedural exposure; assess maternal/infant context